Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

21.32 +0.50 (+2.38%)
Streaming Delayed Price Updated: 3:25 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,902
Open 21.02
Bid (Size) 21.30 (2)
Ask (Size) 21.33 (14)
Prev. Close 20.82
Today's Range 20.96 - 21.56
52wk Range 14.57 - 25.11
Shares Outstanding 29,926,846
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EchoStar, Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+15.7%
+15.7%
1 Month
+13.3%
+13.3%
3 Month
+19.1%
+19.1%
6 Month
+8.2%
+8.2%
1 Year
+0.9%
+0.9%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
A Peek at Fulgent Genetics's Future Earnings
Via Benzinga
Uncovering Potential: Fulgent Genetics's Earnings Preview
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
Fulgent Reports First Quarter 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For May 2, 2025
Via Benzinga
Fulgent Genetics Revenue Tops Estimates
Via The Motley Fool
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2025
Via Benzinga
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Third Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in Upcoming Conferences
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Second Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
From Fulgent Pharma
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
From Fulgent Pharma
Via Business Wire
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
From Fulgent Pharma
Via Business Wire

Frequently Asked Questions

Is Fulgent Genetics, Inc. - Common Stock publicly traded?
Yes, Fulgent Genetics, Inc. - Common Stock is publicly traded.
What exchange does Fulgent Genetics, Inc. - Common Stock trade on?
Fulgent Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fulgent Genetics, Inc. - Common Stock?
The ticker symbol for Fulgent Genetics, Inc. - Common Stock is FLGT on the Nasdaq Stock Market
What is the current price of Fulgent Genetics, Inc. - Common Stock?
The current price of Fulgent Genetics, Inc. - Common Stock is 21.32
When was Fulgent Genetics, Inc. - Common Stock last traded?
The last trade of Fulgent Genetics, Inc. - Common Stock was at 06/06/25 03:25 PM ET
What is the market capitalization of Fulgent Genetics, Inc. - Common Stock?
The market capitalization of Fulgent Genetics, Inc. - Common Stock is 637.89M
How many shares of Fulgent Genetics, Inc. - Common Stock are outstanding?
Fulgent Genetics, Inc. - Common Stock has 638M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.